p53, the tumour suppressor and transcriptional activator, is regulated by numerous post-translational modifications, including lysine methylation. Histone lysine methylation has recently been shown to be reversible; however, it is not known whether non-histone proteins are substrates for demethylation. Here we show that, in human cells, the histone lysine-specific demethylase LSD1 (refs 3, 4) interacts with p53 to repress p53-mediated transcriptional activation and to inhibit the role of p53 in promoting apoptosis. We find that, in vitro, LSD1 removes both monomethylation (K370me1) and dimethylation (K370me2) at K370, a previously identified Smyd2-dependent monomethylation site. However, in vivo, LSD1 shows a strong preference to reverse K370me2, which is performed by a distinct, but unknown, methyltransferase. Our results indicate that K370me2 has a different role in regulating p53 from that of K370me1: K370me1 represses p53 function, whereas K370me2 promotes association with the coactivator 53BP1 (p53-binding protein 1) through tandem Tudor domains in 53BP1. Further, LSD1 represses p53 function through the inhibition of interaction of p53 with 53BP1. These observations show that p53 is dynamically regulated by lysine methylation and demethylation and that the methylation status at a single lysine residue confers distinct regulatory output. Lysine methylation therefore provides similar regulatory complexity for non-histone proteins and for histones.
Specific sites of lysine methylation on histones correlate with either activation or repression of transcription. The tumour suppressor p53 (refs 4-7) is one of only a few non-histone proteins known to be regulated by lysine methylation. Here we report a lysine methyltransferase, Smyd2, that methylates a previously unidentified site, Lys 370, in p53. This methylation site, in contrast to the known site Lys 372, is repressing to p53-mediated transcriptional regulation. Smyd2 helps to maintain low concentrations of promoter-associated p53. We show that reducing Smyd2 concentrations by short interfering RNA enhances p53-mediated apoptosis. We find that Set9-mediated methylation of Lys 372 inhibits Smyd2-mediated methylation of Lys 370, providing regulatory cross-talk between post-translational modifications. In addition, we show that the inhibitory effect of Lys 372 methylation on Lys 370 methylation is caused, in part, by blocking the interaction between p53 and Smyd2. Thus, similar to histones, p53 is subject to both activating and repressing lysine methylation. Our results also predict that Smyd2 may function as a putative oncogene by methylating p53 and repressing its tumour suppressive function.
SUMMARYTP53 is the most frequently mutated gene among all human cancers. Prevalent p53 missense mutations abrogate its tumor suppressive function and lead to “gain-of-function” (GOF) that promotes cancer. Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases KMT2A (MLL1) and KMT2D (MLL2), and acetyltransferase KAT6A (MOZ or MYST3), resulting in genome-wide increases of histone methylation and acetylation. Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumors, but not in p53 wildtype or p53 null tumors. Cancer cell proliferation is dramatically lowered by genetic knockdown of MLL1, or by pharmacological inhibition of the MLL1 methyltransferase complex. Our study reveals a novel chromatin mechanism underlying the progression of tumors with GOF p53, and suggests new possibilities for designing combinatorial chromatin-based therapies for treating individual cancers driven by prevalent GOF p53 mutations.
Histone monoubiquitylation is implicated in critical regulatory processes. We explored the roles of histone H2B ubiquitylation in human cells by reducing the expression of hBRE1/RNF20, the major H2B-specific E3 ubiquitin ligase. While H2B ubiquitylation is broadly associated with transcribed genes, only a subset of genes was transcriptionally affected by RNF20 depletion and abrogation of H2B ubiquitylation. Gene expression dependent on RNF20 includes histones H2A and H2B and the p53 tumor suppressor. In contrast, RNF20 suppresses the expression of several proto-oncogenes, which reside preferentially in closed chromatin and are modestly transcribed despite bearing marks usually associated with high transcription rates. Remarkably, RNF20 depletion augmented the transcriptional effects of epidermal growth factor (EGF), increased cell migration, and elicited transformation and tumorigenesis. Furthermore, frequent RNF20 promoter hypermethylation was observed in tumors. RNF20 may thus be a putative tumor suppressor, acting through selective regulation of a distinct subset of genes.[Keywords: RNF20; BRE1; H2B ubiquitylation; tumor suppressor; transcription] Supplemental material is available at http://www.genesdev.org. Received June 6, 2008; revised version accepted August 12, 2008. Eukaryotic DNA is packaged into a chromatin structure of repeating nucleosomes consisting of DNA wrapped around an octamer of core histone proteins (H2A, H2B, H3, and H4). The histone tails, which protrude from the nucleosome, are subjected to a multitude of covalent modifications believed to play a vital role in chromatin remodeling and transcriptional regulation (Jenuwein and Allis 2001;Berger 2007;. One such modification is histone H2B monoubiquitylation. In the yeast S. cerevisiae this process is mediated by the E3 ligase BRE1 (Hwang et al. 2003). In mammals, the hBRE1(RNF20)/RNF40 complex was shown to function as the relevant E3 ligase (Kim et al. 2005;Zhu et al. 2005). In yeast, transcription of several inducible genes is impaired in the absence of ubiquitylated H2B (H2Bub) (Kao et al. 2004). Increased levels of H2Bub occur on the GAL1 core promoter and throughout the transcribed region upon transcriptional activation, with both ubiquitylation and deubiquitylation being required for optimal transcription (Henry et al. 2003;Xiao et al. 2005). Moreover, H2B monoubiquitylation was shown to lead to H3 methylation on Lys 4 and Lys 79, considered marks of actively transcribed genes (Briggs et al. 2002;Sun and Allis 2002). Yet, a recent study suggests that H2B ubiquitylation in S. pombe controls transcriptional elongation by RNA polymerase II (Pol II) independently of H3 methylation (Tanny et al. 2007).Along with the studies linking H2Bub positively with active transcription, other reports suggest a link between
A paradox of tumor immunology is that tumor-infiltrating lymphocytes are dysfunctional in situ, yet are capable of stem cell–like behavior including self-renewal, expansion, and multipotency, resulting in the eradication of large metastatic tumors. We find that the overabundance of potassium in the tumor microenvironment underlies this dichotomy, triggering suppression of T cell effector function while preserving stemness. High levels of extracellular potassium constrain T cell effector programs by limiting nutrient uptake, thereby inducing autophagy and reduction of histone acetylation at effector and exhaustion loci, which in turn produces CD8+ T cells with improved in vivo persistence, multipotency, and tumor clearance. This mechanistic knowledge advances our understanding of T cell dysfunction and may lead to novel approaches that enable the development of enhanced T cell strategies for cancer immunotherapy.
Following its tyrosine phosphorylation, STAT3 is methylated on K140 by the histone methyl transferase SET9 and demethylated by LSD1 when it is bound to a subset of the promoters that it activates. Methylation of K140 is a negative regulatory event, because its blockade greatly increases the steady-state amount of activated STAT3 and the expression of many (i.e., SOCS3) but not all (i.e., CD14) STAT3 target genes. Biological relevance is shown by the observation that overexpression of SOCS3 when K140 cannot be methylated blocks the ability of cells to activate STAT3 in response to IL-6. K140 methylation does not occur with mutants of STAT3 that do not enter nuclei or bind to DNA. Following treatment with IL-6, events at the SOCS3 promoter occur in an ordered sequence, as shown by chromatin immunoprecipitations. Y705-phosphoryl-STAT3 binds first and S727 is then phosphorylated, followed by the coincident binding of SET9 and dimethylation of K140, and lastly by the binding of LSD1. We conclude that the lysine methylation of promoter-bound STAT3 leads to biologically important down-regulation of the dependent responses and that SET9, which is known to help provide an activating methylation mark to H3K4, is recruited to the newly activated SOCS3 promoter by STAT3. (2) and some of the same lysine side chains can be either methylated or acetylated. These modifications alter chromatin structure, often by providing entry sites for proteins that determine higher-order chromatin organization, leading to the activation or inactivation of specific genes. In addition, methylation and demethylation of p53 and NFκB are carried out by enzymes previously known to modify only histones. For p53, the reactions occur on K370, K372, and K382 (3). For NFκB, K37 is methylated by SET9 (4), and K218 and K221 are methylated by NSD1 and demethylated by FBXL11 (5).STAT3 is phosphorylated on tyrosine and serine residues in response to many different cytokines and growth factors, leading to the formation of dimers through reciprocal phosphotyrosine-SH2 interactions (6). Activated STAT3 dimers bind to and activate the promoters of target genes. In addition to phosphorylation, STAT3 was reported to be acetylated at K685 following cytokine stimulation, and the K685R mutation blocked its activation (7), but these observations have been disputed (8). Ray et al. (9) reported that K49 and K87 of STAT3 are acetylated by p300 and that the K-R mutations resulted in a STAT3 protein that is able to translocate into nuclei, but unable to bind to p300. Here, we show that, in response to IL-6, STAT3 is methylated on K140 by the H3K4 methyl transferase SET9 and demethylated by the H3K4 demethylase LSD1 (lysine-specific demethylase 1, also named BHC110). Prevention of methylation by mutation of K140 greatly enhances the induction of one group of genes in response to IL-6, but has little effect on a second group, and inhibits the activation of a third group. Several lines of evidence indicate that methylation takes place as STAT3 is bound to promoters in the f...
SUMMARY p53 is critical in regulating the differentiation of ES and induced pluripotent stem (iPS) cells. Here, we report a whole-genome study of p53-mediated DNA damage signaling in mouse ES cells. Systems analyses reveal that binding of p53 at promoter region significantly correlates with gene activation but not with repression. Unexpectedly, we identify a regulatory mode for p53-mediated repression through interfering with distal enhancer activity. Importantly, many ES cell-enriched core transcription factors are p53-repressed genes. Further analyses demonstrate that p53-repressed genes are functionally associated with ES/iPS cell status while p53-activated genes are linked to differentiation. p53-activated genes and -repressed genes also display distinguishable features of expression levels and epigenetic markers. Upon DNA damage, p53 regulates the self-renewal and pluripotency of ES cells. Together, these results support a model that, in response to DNA damage, p53 affects the status of ES cells through activating differentiation-associated genes and repressing ES cell-enriched genes.
The tumor suppressor p53 is regulated by numerous posttranslational modifications. Lysine methylation has recently emerged as a key post-translational modification that alters the activity of p53. Here, we describe a novel lysine methylation site in p53 that is carried out by two homologous histone methyltransferases, G9a and Glp. G9a and Glp specifically methylate p53 at Lys 373 , resulting mainly in dimethylation. During DNA damage, the overall level of p53 modified at Lys 373 me2 does not increase, despite the dramatic increase in total p53, indicating that Lys 373 me2 correlates with inactive p53. Further, reduction of G9a and/or Glp levels leads to a larger population of apoptotic cells. Examination of the Oncomine data base shows that G9a and Glp are overexpressed in various cancers compared with corresponding normal tissues, suggesting that they are putative oncogenes. These data reveal a new methylation site within p53 mediated by the methylases G9a and Glp and indicate that G9a is a potential inhibitory target for cancer treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.